LLY

985.76

+1.21%↑

JNJ

223.6

+0.4%↑

ABBV

205.36

+0.4%↑

UNH

382.72

+1.72%↑

AZN

184.08

-0.73%↓

LLY

985.76

+1.21%↑

JNJ

223.6

+0.4%↑

ABBV

205.36

+0.4%↑

UNH

382.72

+1.72%↑

AZN

184.08

-0.73%↓

LLY

985.76

+1.21%↑

JNJ

223.6

+0.4%↑

ABBV

205.36

+0.4%↑

UNH

382.72

+1.72%↑

AZN

184.08

-0.73%↓

LLY

985.76

+1.21%↑

JNJ

223.6

+0.4%↑

ABBV

205.36

+0.4%↑

UNH

382.72

+1.72%↑

AZN

184.08

-0.73%↓

LLY

985.76

+1.21%↑

JNJ

223.6

+0.4%↑

ABBV

205.36

+0.4%↑

UNH

382.72

+1.72%↑

AZN

184.08

-0.73%↓

Home・Elenco Azioni・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Aperta

SettoreSettore sanitario

37.26 -0.93

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

35.54

Massimo

37.93

Metriche Chiave
By Trading Economics
Entrata	7.3M -123M
Vendite	3.7M 3.9M
EPS	-1.29
Margine di Profitto	-3,161.261
Dipendenti	594
EBITDA	20M -122M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+128.79% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-140M 4.3B
Apertura precedente	38.19
Chiusura precedente	37.26

Notizie sul Sentiment di mercato

By Acuity

63%

37%

307 / 346 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

30.39 / 33.46 Supporto e resistenza

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 mag 2026, 22:15 UTC

Acquisizioni, Fusioni, Takeovers

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 mag 2026, 23:46 UTC

Discorsi di Mercato

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 mag 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 mag 2026, 23:33 UTC

Discorsi di Mercato

Gold Rises on Possible Position Adjustments -- Market Talk

11 mag 2026, 22:37 UTC

Discorsi di Mercato

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 mag 2026, 22:32 UTC

Utili

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 mag 2026, 22:02 UTC

Discorsi di Mercato

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 mag 2026, 21:49 UTC

Utili

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 mag 2026, 21:42 UTC

Discorsi di Mercato

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 mag 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 mag 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 mag 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 mag 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 mag 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 mag 2026, 21:23 UTC

Acquisizioni, Fusioni, Takeovers

CSG Systems Sale to NEC Gets CFIUS Clearance

11 mag 2026, 21:12 UTC

Utili

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 mag 2026, 21:12 UTC

Utili

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

11 mag 2026, 20:44 UTC

Utili

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 mag 2026, 20:43 UTC

Utili

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 mag 2026, 20:32 UTC

Utili

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 mag 2026, 20:32 UTC

Utili

CleanSpark 2Q Rev $136.4M >CLSK

11 mag 2026, 20:30 UTC

Utili

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 mag 2026, 20:30 UTC

Utili

Steris 4Q Cont Ops EPS $2.24 >STE

11 mag 2026, 20:30 UTC

Utili

Steris 4Q Rev $1.6B >STE

11 mag 2026, 20:30 UTC

Utili

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 mag 2026, 20:30 UTC

Utili

Steris 4Q Adj EPS $2.83 >STE

11 mag 2026, 20:22 UTC

Azioni calde

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 mag 2026, 19:37 UTC

Utili

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 mag 2026, 19:32 UTC

Discorsi di Mercato

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

128.79% in crescita

Previsioni per 12 mesi

Media 85.75 USD 128.79%

Alto 97 USD

Basso 67 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

307 / 346 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.